Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03140254 · ClinicalTrials.gov registry record · Phase 2

Evaluating Safety and Effectiveness of Octenidine Dihydrochloride

A Phase 2 study, sponsored by C. R. Bard.

Completed
Registry status
Phase 2
Development phase
145
Enrollment target

NCT03140254 is a Phase 2 study that has completed, run by C. R. Bard. The registered enrollment target is 145 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03140254, a Phase 2 study, has completed, sponsored by C. R. Bard.

COMPLETED
Registry status
Phase 2
Development phase
145 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of a topical antiseptic for preoperative skin preparation

Interventions

  • DRUG Placebo
  • DRUG Chlorhexidine gluconate
  • DRUG N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride

Trial Details

FieldValue
Enrollment Target 145 participants
Start Date 2016-09
Est. Completion 2017-03-17
Phase Phase 2

Sponsor

C. R. Bard

75 total trials

What the Registry Record Tells You About NCT03140254

The ClinicalTrials.gov registry entry for NCT03140254 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C. R. Bard, which has 75 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT03140254 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03140254 about?

NCT03140254 is a clinical study titled "Evaluating Safety and Effectiveness of Octenidine Dihydrochloride". The purpose of this study is to evaluate the safety and effectiveness of a topical antiseptic for preoperative skin preparation

What is the current status of trial NCT03140254?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2016-09. Estimated completion is 2017-03-17.

What interventions are being tested in trial NCT03140254?

The interventions under investigation include: Placebo (DRUG), Chlorhexidine gluconate (DRUG), N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride (DRUG).

Who is sponsoring clinical trial NCT03140254?

This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.